Literature DB >> 21623170

MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks.

Michael Fraser1, Shane M Harding, Helen Zhao, Carla Coackley, Daniel Durocher, Robert G Bristow.   

Abstract

AKT is hyper-activated in many human cancers and promotes proliferation and cancer cell survival in response to DNA damaging agents. Ionizing radiation (IR) produces DNA double strand breaks (DSB) and activates AKT, however a direct mechanism linking intra-nuclear DSB and AKT signaling is lacking. Here we demonstrate that AKT is phosphorylated following IR in benign and malignant cells and, using colony-forming assays and in vitro rejoining assays, show that AKT promotes non-homologous end joining-mediated DSB repair and cell survival following IR. Further studies revealed that pAKT-S473, but not pAKT-T308 or total AKT, accumulates in the vicinity of IR-induced DSB and co-localizes with γH2AX and ATM-pSer1981. Based on whole-cell IR, nuclear UV microbeam, and endonuclease-induced DSB studies, we observed that pAKT-S473 is up-regulated by a DSB-induced signaling cascade, and this is dependent on the DSB sensor protein, MRE11. MRE11-dependent pAKT-S473 did not require the MRE11 endonuclease domain. The histone ubiquitin ligase RNF168 is also required for DSB-induced pAKT-S473, and DSB-induced pAKT-S473 is independent of DNA-PKcs, PI3K, and ATR. These data demonstrate that DSB activate a signaling cascade that directly promotes a PI3K-independent pathway of AKT phosphorylation that is dependent on MRE11-ATM-RNF168 signaling. Thus, these data directly link the presence of DNA breaks to AKT-mediated cell survival and support AKT as a target for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21623170     DOI: 10.4161/cc.10.13.16305

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  56 in total

Review 1.  PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

2.  TOP2β-Dependent Nuclear DNA Damage Shapes Extracellular Growth Factor Responses via Dynamic AKT Phosphorylation to Control Virus Latency.

Authors:  Hui-Lan Hu; Lora A Shiflett; Mariko Kobayashi; Moses V Chao; Angus C Wilson; Ian Mohr; Tony T Huang
Journal:  Mol Cell       Date:  2019-03-28       Impact factor: 17.970

3.  Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.

Authors:  Sarah E Golding; Elizabeth Rosenberg; Bret R Adams; Shayalini Wignarajah; Jason M Beckta; Mark J O'Connor; Kristoffer Valerie
Journal:  Cell Cycle       Date:  2012-03-15       Impact factor: 4.534

4.  Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle.

Authors:  Guillermo Risso; Federico Pelisch; Berta Pozzi; Pablo Mammi; Matías Blaustein; Alejandro Colman-Lerner; Anabella Srebrow
Journal:  Cell Cycle       Date:  2013-08-27       Impact factor: 4.534

5.  The Future of Radiobiology.

Authors:  David G Kirsch; Max Diehn; Aparna H Kesarwala; Amit Maity; Meredith A Morgan; Julie K Schwarz; Robert Bristow; Sandra Demaria; Iris Eke; Robert J Griffin; Daphne Haas-Kogan; Geoff S Higgins; Alec C Kimmelman; Randall J Kimple; Isabelle M Lombaert; Li Ma; Brian Marples; Frank Pajonk; Catherine C Park; Dörthe Schaue; Phuoc T Tran; Eric J Bernhard
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

6.  Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.

Authors:  Karim Nacerddine; Jean-Bernard Beaudry; Vasudeva Ginjala; Bart Westerman; Francesca Mattiroli; Ji-Ying Song; Henk van der Poel; Olga Balagué Ponz; Colin Pritchard; Paulien Cornelissen-Steijger; John Zevenhoven; Ellen Tanger; Titia K Sixma; Shridar Ganesan; Maarten van Lohuizen
Journal:  J Clin Invest       Date:  2012-04-16       Impact factor: 14.808

Review 7.  Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.

Authors:  Pau Castel; Eneda Toska; Zachary S Zumsteg; F Javier Carmona; Moshe Elkabets; Ana Bosch; Maurizio Scaltriti
Journal:  Mol Cell Oncol       Date:  2014-10-29

Review 8.  Role of AKT signaling in DNA repair and clinical response to cancer therapy.

Authors:  Qun Liu; Kristen M Turner; W K Alfred Yung; Kexin Chen; Wei Zhang
Journal:  Neuro Oncol       Date:  2014-05-07       Impact factor: 12.300

9.  Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.

Authors:  Nishant Gandhi; Aaron T Wild; Sivarajan T Chettiar; Khaled Aziz; Yoshinori Kato; Rajendra P Gajula; Russell D Williams; Jessica A Cades; Anvesh Annadanam; Danny Song; Yonggang Zhang; Russell K Hales; Joseph M Herman; Elwood Armour; Theodore L DeWeese; Edward M Schaeffer; Phuoc T Tran
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

10.  Akt promotes tumorigenesis in part through modulating genomic instability via phosphorylating XLF.

Authors:  Wenjian Gan; Pengda Liu; Wenyi Wei
Journal:  Nucleus       Date:  2015-07-30       Impact factor: 4.197

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.